Pharma & Biotech Global Week in Review 22 December 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US: On remand, Federal Circuit (once again) decides in favor of patent eligibility for methods of treatment and diagnostic tests: Prometheus v. Mayo (Holman’s Biotech IP Blog) (Patent Docs) (IPBiz)

Canada’s data protection regime upheld: Apotex Inc. v. Canada (Health) (Patent Docs)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

IGC makes significant progress, sets the stage for working groups on GRs and TK (WIPO) (IP Watch)

Officials work to advance WIPO treaty to protect biological, traditional resources (IP Watch)

Canada / EU: IP on Pharma could be main CETA stumbling block (Michael Geist)

Canada’s data protection regime upheld: Apotex Inc. v. Canada (Health) (Patent Docs)

EU: Europe told of obligations on virus benefit-sharing (IP Watch)

Italy: The ‘warning’ by the Italian Antitrust Authority on the authorisation of generic drugs and patent litigation (Kluwer Patent Blog)

UK: When can a third party gain access to documents from discontinued litigation? Pfizer Health AB & Anor v Schwarz Pharma AG & Ors (PatLit)

US: Briefing updates – AMP v. USPTO (Patent Docs) (Patent Docs) (Patent Docs)

US: The relevance of patent exhaustion in the Myriad Genetics case (Patent Docs)

US: Examiner seeks rare rehearing at BPAI: Lab. Corp. of Am. Holdings v. Metabolite Labs. (Patents Post Grant Blog)

US: On remand, Federal Circuit (once again) decides in favor of patent eligibility for methods of treatment and diagnostic tests: Prometheus v. Mayo (Holman’s Biotech IP Blog) (Patent Docs) (IPBiz)

US: Anticancer files patent infringement suit against Cellsight over their fluorescence optical imaging service (Patent Docs)

US: Precision BioSciences files for declaratory judgment of non-infringement of Cellectis patent in connection with its directed nuclease editor technology (Patent Docs)

US: Former Professor fails to dismiss St. John’s patent research suit: St John’s University v Sanford M Bolton et al (Patent Docs)

US: Affymetrix granted summary judgment for noninfingement of Illumina gene sequencing patents (Patent Docs)

 

Products

Actonel (Risedronate sodium) – US: Patent infringement complaint filed following a Paragraph IV certification: Warner Chilcott Co. LLC et al. v. Sun Pharma Global Inc. (Patent Docs)

Crestor (Rosuvastatin) – US: District Court dismisses AstraZeneca’s patent suits against Crestor ANDA applicants who filed section viii statements, finding no valid claims under 35 USC 271(e)(2) (Orange Book Blog)

Exalgo (Hydromorphone hydrochloride) – US: Patent infringement complaint filed following a Paragraph IV certification: Mallinckrodt Inc. v. Watson Laboratories, Inc.-Florida (Patent Docs)

FazaClo (Clozapine): US – Patent infringement complaint filed following a Paragraph IV certification: Mylan Pharmaceuticals Inc. v. Ethypharm SA et al. (Patent Docs)

Hydroxypropyl methylcellulose – Hungary: Metropolitan Appeal Court confirms rejection of request for preliminary injunction (EPLAW)

Ibuprofen – US: False marking complaint based on Pfizer’s marking of its Advil Ibuprofen Caplets: San Francisco Technology Inc. v. Pfizer Inc. (Patent Docs)

Lovenox (Enoxaparin) – US: Sanofi seeks summary judgment in generic Lovenox dispute; administrative record highlights disagreements at FDA over generic approval (FDA Law Blog)

Orapred ODT (Prednisolone) – US: Patent infringement complaint filed following a Paragraph IV certification: Shionogi Pharma Inc. et al. v. Mylan Inc. et al. (Patent Docs) (IPBiz) (SmartBrief)

Protopic (Tacrolimus) – US: Patent infringement complaint filed following a Paragraph IV certification: Astellas US LLC et al. v. Nycomed U.S. Inc. (Patent Docs)

Resverol (Resveratrol) – EU: General Court confirms likelihood of confusion between RESVEROL and LESTEROL: Longevity Health Products V OHIM – Gruppo Lepetit (RESVEROL) (Class 46)

Silenor (Doxepin) – US: Patent infringement complaint filed following a Paragraph IV certification: Somaxon Pharmaceuticals Inc. et al. v. Actavis Elizabeth LLC et al (Patent Docs)

Solodyn (Minocycline) – US: Patent infringement complaint filed following a Paragraph IV certification: Medicis Pharmaceutical Corp. v. Aurobindo Pharma Ltd. et al. (Patent Docs)

Tolposan – EU: General Court: TOLPOSAN v. TONOPAN – no likelihood of confusion: Novartis v OHMI – Sanochemia Pharmazeutika (TOLPOSAN) (Class 46)

Vanos (Fluocinonide) – US: Patent infringement complaint filed following a Paragraph IV certification: Medicis Pharmaceutical Corp. v. Nycomed US Inc. (Patent Docs)

Yaz (Drospirenone, Ethinyl estradiol) – Bayer settles with Teva in multiple Yaz patent disputes: Bayer v Teva (Patent Docs)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: